Soleno Therapeutics (SLNO) Net Income towards Common Stockholders (2013 - 2026)
Soleno Therapeutics (SLNO) reported Net Income towards Common Stockholders of $31.4 million for Q1 2026, up 171.68% year-over-year from $11.5 million in Q1 2025, and down 27.63% quarter-over-quarter from $43.4 million in Q4 2025.
Soleno Therapeutics (SLNO) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 13 years of Net Income towards Common Stockholders data on file, last reported at $31.4 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at $31.4 million, up 171.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $96.0 million (up 148.51% YoY), and the FY2025 annual result was $20.9 million, up 111.88% from the prior year.
- Net Income towards Common Stockholders eased to $31.4 million in Q1 2026 per SLNO's latest filing, from $43.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $43.4 million in Q4 2025 and troughed at -$76.6 million in Q3 2024.
- A 5-year average of -$11.0 million and a median of -$8.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders sank 650.55% in 2024, then soared 177.77% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$5.6 million in 2022, then tumbled by 109.73% to -$11.8 million in 2023, then sank by 373.83% to -$55.8 million in 2024, then soared by 177.77% to $43.4 million in 2025, then declined by 27.63% to $31.4 million in 2026.
- Business Quant data shows SLNO's Net Income towards Common Stockholders at $31.4 million in Q1 2026, $43.4 million in Q4 2025, and $26.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 31.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.38 Mn |
| Dec 31, 2025 | 43.36 Mn |
| Sep 30, 2025 | 26.01 Mn |
| Jun 30, 2025 | -4.71 Mn |
| Mar 31, 2025 | -43.77 Mn |
| Dec 31, 2024 | -55.75 Mn |
| Sep 30, 2024 | -76.62 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Mar 31, 2024 | -21.40 Mn |
| Dec 31, 2023 | -11.77 Mn |
| Sep 30, 2023 | -10.21 Mn |
| Jun 30, 2023 | -8.48 Mn |
| Mar 31, 2023 | -8.36 Mn |
| Dec 31, 2022 | -5.61 Mn |
| Sep 30, 2022 | -6.24 Mn |
| Jun 30, 2022 | -6.78 Mn |
| Mar 31, 2022 | -5.77 Mn |
| Dec 31, 2021 | -3.00 Mn |
| Sep 30, 2021 | -8.29 Mn |
| Jun 30, 2021 | -11.09 Mn |